VEGF antagonist formulations suitable for intravitreal administration
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
1. A formulation suitable for intravitreal administration comprising:
(a) 1 mg/mL to 100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist;
(b) an organic co-solvent;
(c) 5 mM to 40 mM of a phosphate buffer; and
(d) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;
wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.
2. The formulation of claim 1 , wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.
3. The formulation of claim 2 , wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.
4. The formulation of claim 3 , wherein the VEGF antagonist is a dimer of the fusion protein.
5. The formulation of claim 1 , wherein the organic co-solvent is polysorbate 20.
6. The formulation of claim 1 , wherein the phosphate buffer is sodium phosphate buffer.
7. The formulation of claim 1 , wherein the stabilizing agent is sucrose.
8. A formulation suitable for intravitreal administration comprising:
(a) 40 mg/mL of a fusion protein comprising amino acids 27-475 of SEQ ID NO:4;
(b) 0.03% polysorbate 20;
(c) 10 mM sodium phosphate buffer, pH 6.2; and
(d) 5% sucrose.
9. A method of maintaining stability of a formulation, comprising the steps of:
(a) adding a vascular endothelial growth factor (VEGF) antagonist to a solution at a concentration of from 1 mg/ml to 100 mg/ml, wherein the solution comprises:
(i) an organic co-solvent;
(ii) 5 mM to 40 mM of a phosphate buffer; and
(iii) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;
wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component; and
(b) maintaining the formulation over a period of time of from 1 month to 24 months whereby the formulation remain suitable for intravitreal administration.
10. The method of claim 9 , wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.
11. The method of claim 10 , wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.
12. The method of claim 11 , wherein the VEGF antagonist is a dimer of the fusion protein.
13. The method of claim 9 , wherein the organic co-solvent is polysorbate 20.
14. The method of claim 9 , wherein the phosphate buffer is sodium phosphate buffer.
15. The method of claim 9 , wherein the stabilizing agent is sucrose.